Cell therapy is emerging, cell by cell, into the repertoire of medical therapies. However, it still has not broken into mainstream use. For instance, there are only two FDA-approved chimeric antigen receptor (CAR) T-cell treatments in the United States: Kymirah, Novartis’s treatment for acute lymphoblastic leukemia, and Yescarta, Kite Pharma’s treatment for non-Hodgkin’s lymphoma.
The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced today the findings of an independent economic impact study detailing the economic development contributions of TEDCO’s five core programs to the state of Maryland.
Visibility, speaking out, courage and organization. Forty years ago, these were the things that brought the Orphan Drug Act to life. On Sunday, February 24, across the U.S. and India, over 7,000 supporters gathered in the same passion: speaking out and bringing visibility to the more than 7,000 disorders collectively known as rare diseases, organized under the banner of Racefor7USA and its parent organizations, the Organization for Rare Disease India (ORDI) and Organization for Rare Diseases India in the U.S. (ORDIUSA).
Cutting Edge Lab Space Available
The NIH is the cornerstone to the world scientific community and is the largest life sciences engine in the US.
Bethesda Bio gives life science companies the ability to be on the doorstep of this invaluable wealth of resources, community, talent, technology, intellectual property, clinical studies. The existing Bethesda central business district provides a vibrant live, work and play environment to recruit and retain the best scientific minds. Over the past two decades, Bethesda has been the center of Montgomery County and the hub of innovation.
Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.
An HIV-positive man in Britain has become the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.
Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.
Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence (who have industry experience in therapeutics, Dx, medtech and more) next Wednesday, March 20th. (The next session is scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here(“EIR resource” at BHI). For questions/more information, contact BHI.
More than 120 people registered for last week’s SBIR Workshop organized by BioHealth Innovation in partnership with Launch Workplaces and support from TEDCO and NIH FCU.
The event featured program overviews, “how to” sessions regarding specific aspects of proposal development and 1:1 partnering meetings with the program managers.
Speakers included: Todd Haim, Ph.D., Chief, Office of Small Business Research NIA; Mike Pieck, Ph.D., Small Business Coordinator, NHLBI; Maureen (Cusick) Thomas, Outreach Coordinator, NIA;Victor Prikhodko, Business Advisor, NIDA; Amir Rahbar, PhD, MBA, Program Director, NCI; Vladimir M. Popov, PhD, Business Dev. Manager, NCI-FNL;Amir Rahbar, PhD, MBA, Program Director, NCI; Henry Ahn, Program Director SBIR/STTR, NSF; and Colleen Gibney, SBIR Deputy Project Mgr, USAMRMC.
44% of the attendees had applied for SBIR funding before with half of these innovators receiving a Phase 1. Only 16% had received a Phase II award. The majority of attendees were from Montgomery and Frederick Counties and the City of Baltimore. However, registrants also traveled from Virginia, DC, Illinois and Pennsylvania.
Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.
